Kapil Dhingra

Insider Reports History

Entity
Individual
Location
39 Bliss Avenue, Tenafly, NJ
Signature
/s/ Shawn Glidden, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Kapil Dhingra:

Stock Role Class Num Shares Value Price $ Report Date Ownership
LAVA Therapeutics NV Director Common Shares (Right to Buy) 33.4K Feb 13, 2025 Direct
Replimune Group, Inc. Director Stock Option (right to buy) 32K Apr 1, 2025 Direct
Black Diamond Therapeutics, Inc. Director Stock Option (Right to Buy) 30.6K Jun 6, 2024 Direct
LAVA Therapeutics NV Director Common Shares 30K Jan 1, 2025 Direct
CARGO Therapeutics, Inc. Director Stock Option (Right to Buy) 11.9K Jun 4, 2024 Direct

Insider Reports Filed by Kapil Dhingra

Symbol Company Period Transactions Value $ Form Type Date Filed Role
REPL Replimune Group, Inc. Apr 1, 2025 1 $0 4 Apr 3, 2025 Director
LVTX LAVA Therapeutics NV Feb 13, 2025 1 $0 4 Feb 18, 2025 Director
LVTX LAVA Therapeutics NV Jan 1, 2025 0 $0 3 Jan 2, 2025 Director
BDTX Black Diamond Therapeutics, Inc. Jun 6, 2024 1 $0 4 Jun 6, 2024 Director
CRGX CARGO Therapeutics, Inc. Jun 4, 2024 1 $0 4 Jun 6, 2024 Director
CRGX CARGO Therapeutics, Inc. Apr 15, 2024 1 $0 4 Apr 17, 2024 Director
CRGX CARGO Therapeutics, Inc. Apr 15, 2024 0 $0 3 Apr 17, 2024 Director
REPL Replimune Group, Inc. Apr 1, 2024 1 $0 4 Apr 3, 2024 Director
BDTX Black Diamond Therapeutics, Inc. May 16, 2023 1 $0 4 May 17, 2023 Director
REPL Replimune Group, Inc. Apr 1, 2023 1 $0 4 Apr 4, 2023 Director
BDTX Black Diamond Therapeutics, Inc. Jun 10, 2022 1 $0 4 Jun 13, 2022 Director
REPL Replimune Group, Inc. Apr 1, 2022 1 $0 4 Apr 5, 2022 Director
BDTX Black Diamond Therapeutics, Inc. Jun 18, 2021 1 $0 4 Jun 22, 2021 Director